- call +1-201-465-4211
- email sales@mrinsights.biz
Benign prostatic hyperplasia (BPH) is a condition occurring in men when the prostate gland is enlarged. Benign prostatic hyperplasia is also termed as benign prostatic hypertrophy or benign prostatic obstruction. Prostate gland grows in primarily two phases, firstly during puberty when the size of the prostate doubles and the second growth phase starts at 25 years and continues throughout the lifetime. While the prostate gland enlarges in a man, it presses and pinches the urethra making the bladder wall thick. This pressure and squeeze on the urethra weaken the bladder and makes it lose the ability to empty the urine completely. Urinary retention and narrowing of the urethra can cause many problems which are associated with benign prostatic hyperplasia. Benign prostatic hyperplasia is one of the common prostate problems for men older than age 50.
Scope of the Report:
This report studies the Benign Prostatic Hyperplasia Testing market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Benign Prostatic Hyperplasia Testing market by product type and applications/end industries.
Benign prostatic hyperplasia testing market is primarily driven by a few key factors such as the growing geriatric male population, patient awareness regarding rising healthcare concerns, increase in healthcare expenditure, increasing government initiatives and availability of minimally invasive surgery as a drug replacement, faster and easy performing diagnosis test results. The market is likely to grow owing to the novel diagnostic methods which are accurate than the conventional PSA blood test for benign prostatic hyperplasia which is effective in diagnosis and is expected to fuel the growth of benign prostatic hyperplasia testing market.
However, faces various challenges such as researchers which have found new ways to prevent the disease. Benign prostatic hyperplasia testing market tests are still in the primary stages of development which is a major restraint for the market. Benign Prostatic Hyperplasia Testing Market faces tremendous challenges due to the low awareness regarding the various diseases and diagnostic measures. Low-income countries and rising economies are coming forward to address such issues for benign prostatic hyperplasia testing market.
The global Benign Prostatic Hyperplasia Testing market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Benign Prostatic Hyperplasia Testing.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
AEternaZentaris
Astellas Pharma
Eli Lilly and Company
IntelGenx Technologies Corp
Nymox Pharmaceutical Corporation
Protox Therapeutics
Quest PharmaTech
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Urinalysis
Prostate-Specific Antigen (PSA) Blood Test
Urodynamic Test
Cystoscopy
Market Segment by Applications, can be divided into
Hospitals
Diagnostic Centers
Clinics
Research Institutes
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Benign Prostatic Hyperplasia Testing Market Overview
1.1 Product Overview and Scope of Benign Prostatic Hyperplasia Testing
1.2 Classification of Benign Prostatic Hyperplasia Testing by Types
1.2.1 Global Benign Prostatic Hyperplasia Testing Revenue Comparison by Types (2017-2023)
1.2.2 Global Benign Prostatic Hyperplasia Testing Revenue Market Share by Types in 2017
1.2.3 Urinalysis
1.2.4 Prostate-Specific Antigen (PSA) Blood Test
1.2.5 Urodynamic Test
1.2.6 Cystoscopy
1.3 Global Benign Prostatic Hyperplasia Testing Market by Application
1.3.1 Global Benign Prostatic Hyperplasia Testing Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospitals
1.3.3 Diagnostic Centers
1.3.4 Clinics
1.3.5 Research Institutes
1.4 Global Benign Prostatic Hyperplasia Testing Market by Regions
1.4.1 Global Benign Prostatic Hyperplasia Testing Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Benign Prostatic Hyperplasia Testing Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Benign Prostatic Hyperplasia Testing Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Benign Prostatic Hyperplasia Testing Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Benign Prostatic Hyperplasia Testing Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Benign Prostatic Hyperplasia Testing Status and Prospect (2013-2023)
1.5 Global Market Size of Benign Prostatic Hyperplasia Testing (2013-2023)
2 Manufacturers Profiles
2.1 AEternaZentaris
2.1.1 Business Overview
2.1.2 Benign Prostatic Hyperplasia Testing Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 AEternaZentaris Benign Prostatic Hyperplasia Testing Revenue, Gross Margin and Market Share (2016-2017)
2.2 Astellas Pharma
2.2.1 Business Overview
2.2.2 Benign Prostatic Hyperplasia Testing Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Astellas Pharma Benign Prostatic Hyperplasia Testing Revenue, Gross Margin and Market Share (2016-2017)
2.3 Eli Lilly and Company
2.3.1 Business Overview
2.3.2 Benign Prostatic Hyperplasia Testing Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Eli Lilly and Company Benign Prostatic Hyperplasia Testing Revenue, Gross Margin and Market Share (2016-2017)
2.4 IntelGenx Technologies Corp
2.4.1 Business Overview
2.4.2 Benign Prostatic Hyperplasia Testing Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 IntelGenx Technologies Corp Benign Prostatic Hyperplasia Testing Revenue, Gross Margin and Market Share (2016-2017)
2.5 Nymox Pharmaceutical Corporation
2.5.1 Business Overview
2.5.2 Benign Prostatic Hyperplasia Testing Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Nymox Pharmaceutical Corporation Benign Prostatic Hyperplasia Testing Revenue, Gross Margin and Market Share (2016-2017)
2.6 Protox Therapeutics
2.6.1 Business Overview
2.6.2 Benign Prostatic Hyperplasia Testing Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Protox Therapeutics Benign Prostatic Hyperplasia Testing Revenue, Gross Margin and Market Share (2016-2017)
2.7 Quest PharmaTech
2.7.1 Business Overview
2.7.2 Benign Prostatic Hyperplasia Testing Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Quest PharmaTech Benign Prostatic Hyperplasia Testing Revenue, Gross Margin and Market Share (2016-2017)
3 Global Benign Prostatic Hyperplasia Testing Market Competition, by Players
3.1 Global Benign Prostatic Hyperplasia Testing Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Benign Prostatic Hyperplasia Testing Players Market Share
3.2.2 Top 10 Benign Prostatic Hyperplasia Testing Players Market Share
3.3 Market Competition Trend
4 Global Benign Prostatic Hyperplasia Testing Market Size by Regions
4.1 Global Benign Prostatic Hyperplasia Testing Revenue and Market Share by Regions
4.2 North America Benign Prostatic Hyperplasia Testing Revenue and Growth Rate (2013-2018)
4.3 Europe Benign Prostatic Hyperplasia Testing Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Benign Prostatic Hyperplasia Testing Revenue and Growth Rate (2013-2018)
4.5 South America Benign Prostatic Hyperplasia Testing Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Benign Prostatic Hyperplasia Testing Revenue and Growth Rate (2013-2018)
5 North America Benign Prostatic Hyperplasia Testing Revenue by Countries
5.1 North America Benign Prostatic Hyperplasia Testing Revenue by Countries (2013-2018)
5.2 USA Benign Prostatic Hyperplasia Testing Revenue and Growth Rate (2013-2018)
5.3 Canada Benign Prostatic Hyperplasia Testing Revenue and Growth Rate (2013-2018)
5.4 Mexico Benign Prostatic Hyperplasia Testing Revenue and Growth Rate (2013-2018)
6 Europe Benign Prostatic Hyperplasia Testing Revenue by Countries
6.1 Europe Benign Prostatic Hyperplasia Testing Revenue by Countries (2013-2018)
6.2 Germany Benign Prostatic Hyperplasia Testing Revenue and Growth Rate (2013-2018)
6.3 UK Benign Prostatic Hyperplasia Testing Revenue and Growth Rate (2013-2018)
6.4 France Benign Prostatic Hyperplasia Testing Revenue and Growth Rate (2013-2018)
6.5 Russia Benign Prostatic Hyperplasia Testing Revenue and Growth Rate (2013-2018)
6.6 Italy Benign Prostatic Hyperplasia Testing Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Benign Prostatic Hyperplasia Testing Revenue by Countries
7.1 Asia-Pacific Benign Prostatic Hyperplasia Testing Revenue by Countries (2013-2018)
7.2 China Benign Prostatic Hyperplasia Testing Revenue and Growth Rate (2013-2018)
7.3 Japan Benign Prostatic Hyperplasia Testing Revenue and Growth Rate (2013-2018)
7.4 Korea Benign Prostatic Hyperplasia Testing Revenue and Growth Rate (2013-2018)
7.5 India Benign Prostatic Hyperplasia Testing Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Benign Prostatic Hyperplasia Testing Revenue and Growth Rate (2013-2018)
8 South America Benign Prostatic Hyperplasia Testing Revenue by Countries
8.1 South America Benign Prostatic Hyperplasia Testing Revenue by Countries (2013-2018)
8.2 Brazil Benign Prostatic Hyperplasia Testing Revenue and Growth Rate (2013-2018)
8.3 Argentina Benign Prostatic Hyperplasia Testing Revenue and Growth Rate (2013-2018)
8.4 Colombia Benign Prostatic Hyperplasia Testing Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Benign Prostatic Hyperplasia Testing by Countries
9.1 Middle East and Africa Benign Prostatic Hyperplasia Testing Revenue by Countries (2013-2018)
9.2 Saudi Arabia Benign Prostatic Hyperplasia Testing Revenue and Growth Rate (2013-2018)
9.3 UAE Benign Prostatic Hyperplasia Testing Revenue and Growth Rate (2013-2018)
9.4 Egypt Benign Prostatic Hyperplasia Testing Revenue and Growth Rate (2013-2018)
9.5 Nigeria Benign Prostatic Hyperplasia Testing Revenue and Growth Rate (2013-2018)
9.6 South Africa Benign Prostatic Hyperplasia Testing Revenue and Growth Rate (2013-2018)
10 Global Benign Prostatic Hyperplasia Testing Market Segment by Type
10.1 Global Benign Prostatic Hyperplasia Testing Revenue and Market Share by Type (2013-2018)
10.2 Global Benign Prostatic Hyperplasia Testing Market Forecast by Type (2018-2023)
10.3 Urinalysis Revenue Growth Rate (2013-2023)
10.4 Prostate-Specific Antigen (PSA) Blood Test Revenue Growth Rate (2013-2023)
10.5 Urodynamic Test Revenue Growth Rate (2013-2023)
10.6 Cystoscopy Revenue Growth Rate (2013-2023)
11 Global Benign Prostatic Hyperplasia Testing Market Segment by Application
11.1 Global Benign Prostatic Hyperplasia Testing Revenue Market Share by Application (2013-2018)
11.2 Benign Prostatic Hyperplasia Testing Market Forecast by Application (2018-2023)
11.3 Hospitals Revenue Growth (2013-2018)
11.4 Diagnostic Centers Revenue Growth (2013-2018)
11.5 Clinics Revenue Growth (2013-2018)
11.6 Research Institutes Revenue Growth (2013-2018)
12 Global Benign Prostatic Hyperplasia Testing Market Size Forecast (2018-2023)
12.1 Global Benign Prostatic Hyperplasia Testing Market Size Forecast (2018-2023)
12.2 Global Benign Prostatic Hyperplasia Testing Market Forecast by Regions (2018-2023)
12.3 North America Benign Prostatic Hyperplasia Testing Revenue Market Forecast (2018-2023)
12.4 Europe Benign Prostatic Hyperplasia Testing Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Benign Prostatic Hyperplasia Testing Revenue Market Forecast (2018-2023)
12.6 South America Benign Prostatic Hyperplasia Testing Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Benign Prostatic Hyperplasia Testing Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Benign Prostatic Hyperplasia Testing Picture
Table Product Specifications of Benign Prostatic Hyperplasia Testing
Table Global Benign Prostatic Hyperplasia Testing a
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
